Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., University of Cambridge (United Kingdom) 1993
  • Clinical Research Fellow, Clinical Pharmacology, Medicine, Addenbrooke's Hospital (United Kingdom) 1984 - 1992
  • Senior Medical Training Rotations in General Medicine, Nephrology, Cardiology and ID, Addenbrooke's Hospital (United Kingdom) 1984 - 1987
  • Junior Medical Training Rotations, Guy's Hospital Medical School (United Kingdom) 1981 - 1984
• Recognition
• 

  Awards & Honors

  • Fellowship . The Royal College of Physicians of London. 1998
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • El, K., S. M. Gray, M. E. Capozzi, E. R. Knuth, E. Jin, B. Svendsen, A. Clifford, et al. “GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells.” Sci Adv 7, no. 11 (March 2021). https://doi.org/10.1126/sciadv.abf1948.
       Full Text  Link to Item
    • Nunez, Derek J., Myriam Alexander, Laura Yerges-Armstrong, Gurparkash Singh, Geert Byttebier, Elisa Fabbrini, Dawn Waterworth, et al. “Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.” Am J Physiol Gastrointest Liver Physiol 316, no. 3 (March 1, 2019): G372–86. https://doi.org/10.1152/ajpgi.00051.2018.
       Full Text  Open Access Copy  Link to Item
    • Nunez, Derek J., and David D’Alessio. “Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).” Diabetes Obes Metab 20, no. 2 (February 2018): 233–37. https://doi.org/10.1111/dom.13102.
       Full Text  Open Access Copy  Link to Item
    • Nunez, D. J., X. Yao, J. Lin, A. Walker, P. Zuo, L. Webster, S. Krug-Gourley, M. J. Zamek-Gliszczynski, D. S. Gillmor, and S. L. Johnson. “Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.” Diabetes Obes Metab 18, no. 7 (July 2016): 654–62. https://doi.org/10.1111/dom.12656.
       Full Text  Link to Item
    • Hodge, R. J., and D. J. Nunez. “Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?” Diabetes, Obesity and Metabolism 18, no. 5 (May 2016): 439–43. https://doi.org/10.1111/dom.12636.
       Full Text
    • Lin, J., R. J. Hodge, R. L. O’Connor-Semmes, and D. J. Nunez. “GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.” Diabetes Obes Metab 17, no. 10 (October 2015): 1007–10. https://doi.org/10.1111/dom.12533.
       Full Text  Link to Item
    • Vlasakakis, Georgios, Susan L. Johnson, Jiang Lin, Xiaozhou Yao, Christopher J. Gruenloh, John P. Chism, and Derek J. Nunez. “Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.” Advances in Therapy 32, no. 7 (July 2015): 650–61. https://doi.org/10.1007/s12325-015-0222-4.
       Full Text
    • O’Connor-Semmes, R. L., J. Lin, R. J. Hodge, S. Andrews, J. Chism, A. Choudhury, and D. J. Nunez. “GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety.” Clinical Pharmacology & Therapeutics 96, no. 6 (December 2014): 704–12. https://doi.org/10.1038/clpt.2014.187.
       Full Text
    • Nunez, Derek J., Mark A. Bush, David A. Collins, Susan L. McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow, and Paul L. Feldman. “Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.” Plos One 9, no. 4 (2014): e92494. https://doi.org/10.1371/journal.pone.0092494.
       Full Text  Link to Item
    • Kapur, Anita, Robin O’Connor-Semmes, Elizabeth K. Hussey, Robert L. Dobbins, Wenli Tao, Marcus Hompesch, Glenn A. Smith, et al. “First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.” Bmc Pharmacology and Toxicology 14, no. 1 (December 2013). https://doi.org/10.1186/2050-6511-14-26.
       Full Text
    • Hodge, Rebecca J., Jiang Lin, Lakshmi S. Vasist Johnson, Elizabeth P. Gould, Gary D. Bowers, and Derek J. Nunez. “Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes.” Clinical Pharmacology in Drug Development 2, no. 3 (July 2013): 213–22. https://doi.org/10.1002/cpdd.34.
       Full Text
    • Mudaliar, S., D. A. Armstrong, A. A. Mavian, R. O’Connor-Semmes, P. K. Mydlow, J. Ye, E. K. Hussey, D. J. Nunez, R. R. Henry, and R. L. Dobbins. “Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes.” Diabetes Care 35, no. 11 (November 1, 2012): 2198–2200. https://doi.org/10.2337/dc12-0508.
       Full Text
    • Wagner, J. A., M. Prince, E. C. Wright, M. M. Ennis, J. Kochan, D. J. R. Nunez, B. Schneider, et al. “The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.” Clin Pharmacol Ther 87, no. 5 (May 2010): 539–42. https://doi.org/10.1038/clpt.2009.227.
       Full Text  Link to Item
    • Abbasi, Ali, Anna-Stina Sahlqvist, Luca Lotta, Julia M. Brosnan, Peter Vollenweider, Philippe Giabbanelli, Derek J. Nunez, et al. “A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature.” Plos One 11, no. 10 (n.d.): e0163721–e0163721. https://doi.org/10.1371/journal.pone.0163721.
       Full Text
    • Hodge, Rebecca J., Mark A. Paulik, Ann Walker, Joyce A. Boucheron, Susan L. McMullen, Dawn S. Gillmor, and Derek J. Nunez. “Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.” Plos One 11, no. 4 (n.d.): e0153151–e0153151. https://doi.org/10.1371/journal.pone.0153151.
       Full Text
    • Napolitano, Antonella, Sam Miller, Andrew W. Nicholls, David Baker, Stephanie Van Horn, Elizabeth Thomas, Deepak Rajpal, Aaron Spivak, James R. Brown, and Derek J. Nunez. “Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus.” Plos One 9, no. 7 (n.d.): e100778–e100778. https://doi.org/10.1371/journal.pone.0100778.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.